Insulet (PODD) Competitors $261.68 -7.38 (-2.74%) (As of 12:18 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends PODD vs. ABMD, PEN, BDX, EW, RMD, IDXX, DXCM, STE, BAX, and HOLXShould you be buying Insulet stock or one of its competitors? The main competitors of Insulet include Abiomed (ABMD), Penumbra (PEN), Becton, Dickinson and Company (BDX), Edwards Lifesciences (EW), ResMed (RMD), IDEXX Laboratories (IDXX), DexCom (DXCM), STERIS (STE), Baxter International (BAX), and Hologic (HOLX). These companies are all part of the "medical" sector. Insulet vs. Abiomed Penumbra Becton, Dickinson and Company Edwards Lifesciences ResMed IDEXX Laboratories DexCom STERIS Baxter International Hologic Abiomed (NASDAQ:ABMD) and Insulet (NASDAQ:PODD) are both large-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, profitability, valuation, risk, analyst recommendations, earnings, community ranking, dividends and institutional ownership. Is ABMD or PODD more profitable? Abiomed has a net margin of 24.84% compared to Insulet's net margin of 21.22%. Insulet's return on equity of 27.98% beat Abiomed's return on equity.Company Net Margins Return on Equity Return on Assets Abiomed24.84% 14.77% 13.32% Insulet 21.22%27.98%9.16% Do institutionals and insiders believe in ABMD or PODD? 94.5% of Abiomed shares are owned by institutional investors. 2.5% of Abiomed shares are owned by insiders. Comparatively, 0.5% of Insulet shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Which has better valuation & earnings, ABMD or PODD? Insulet has higher revenue and earnings than Abiomed. Insulet is trading at a lower price-to-earnings ratio than Abiomed, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAbiomed$1.03B16.65$136.51M$5.8265.47Insulet$1.70B11.12$206.30M$5.8446.07 Which has more risk & volatility, ABMD or PODD? Abiomed has a beta of 1.4, suggesting that its stock price is 40% more volatile than the S&P 500. Comparatively, Insulet has a beta of 1.22, suggesting that its stock price is 22% more volatile than the S&P 500. Does the MarketBeat Community believe in ABMD or PODD? Insulet received 188 more outperform votes than Abiomed when rated by MarketBeat users. Likewise, 66.15% of users gave Insulet an outperform vote while only 60.52% of users gave Abiomed an outperform vote. CompanyUnderperformOutperformAbiomedOutperform Votes53560.52% Underperform Votes34939.48% InsuletOutperform Votes72366.15% Underperform Votes37033.85% Do analysts recommend ABMD or PODD? Insulet has a consensus target price of $253.27, indicating a potential downside of 5.87%. Given Insulet's stronger consensus rating and higher possible upside, analysts plainly believe Insulet is more favorable than Abiomed.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Abiomed 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Insulet 0 Sell rating(s) 3 Hold rating(s) 12 Buy rating(s) 0 Strong Buy rating(s) 2.80 Does the media prefer ABMD or PODD? In the previous week, Insulet had 47 more articles in the media than Abiomed. MarketBeat recorded 47 mentions for Insulet and 0 mentions for Abiomed. Insulet's average media sentiment score of 0.80 beat Abiomed's score of 0.44 indicating that Insulet is being referred to more favorably in the news media. Company Overall Sentiment Abiomed Neutral Insulet Positive SummaryInsulet beats Abiomed on 11 of the 18 factors compared between the two stocks. Ad DarwinNew Year, New Opportunity! 2 AI Stocks Under $10 Ready to SoarAs we step into 2025, artificial intelligence (AI) stocks continue to dominate headlines, and now is the perfect moment to position yourself for the coming year’s potential. Our latest research has uncovered two must-buy AI stocks currently trading under $10/share – an affordable entry with promising growth potential. These stocks are flying under the radar, but it’s only a matter of time before they gain mainstream attention.👉 Click here to access your FREE report now! Get Insulet News Delivered to You Automatically Sign up to receive the latest news and ratings for PODD and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PODD vs. The Competition Export to ExcelMetricInsuletSurgical & medical instruments IndustryMedical SectorNASDAQ ExchangeMarket Cap$18.87B$4.61B$5.21B$8.94BDividend YieldN/A39.52%4.98%4.03%P/E Ratio46.0724.36133.9017.28Price / Sales11.1262.761,274.4091.64Price / Cash72.4952.4438.8936.42Price / Book16.885.616.395.98Net Income$206.30M$13.58M$118.47M$225.08M7 Day Performance9.83%-0.19%-1.97%-0.37%1 Month Performance15.72%7.12%2.62%4.23%1 Year Performance55.57%55.11%36.42%27.64% Insulet Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PODDInsulet4.4324 of 5 stars$261.68-2.7%$253.27-3.2%+64.4%$18.35B$1.70B44.813,000Analyst ForecastAnalyst RevisionABMDAbiomedN/A$381.02flatN/A+0.0%$17.18B$1.03B65.472,003Analyst ForecastPENPenumbra4.1597 of 5 stars$236.45+1.5%N/A+13.1%$9.07B$1.06B274.944,200BDXBecton, Dickinson and Company4.9519 of 5 stars$231.64+2.0%N/A-2.0%$69.39B$19.37B47.6673,000Earnings ReportDividend IncreaseShort Interest ↓Analyst RevisionHigh Trading VolumeEWEdwards Lifesciences4.5714 of 5 stars$66.23+0.6%N/A+3.0%$39.06B$6.31B9.5619,800Insider SellingShort Interest ↓RMDResMed4.7595 of 5 stars$252.38+1.5%N/A+64.8%$37.05B$4.69B33.439,980Insider SellingAnalyst RevisionPositive NewsIDXXIDEXX Laboratories4.8889 of 5 stars$433.28+0.1%N/A-0.6%$35.48B$3.66B41.7811,000Short Interest ↓Positive NewsDXCMDexCom4.9837 of 5 stars$69.96+1.5%N/A-26.3%$26.80B$3.62B41.899,600Short Interest ↑Positive NewsSTESTERIS4.9614 of 5 stars$219.19+1.7%N/A+9.9%$21.62B$5.14B50.0418,179Short Interest ↓BAXBaxter International4.7982 of 5 stars$34.64-3.9%N/A-3.2%$18.42B$14.81B7.1360,000Earnings ReportDividend CutAnalyst ForecastShort Interest ↓High Trading VolumeHOLXHologic4.8889 of 5 stars$78.76-0.7%N/A+10.9%$18.29B$4.03B23.656,990Analyst UpgradeShort Interest ↓Analyst Revision Related Companies and Tools Related Companies Abiomed Alternatives Penumbra Alternatives Becton, Dickinson and Company Alternatives Edwards Lifesciences Alternatives ResMed Alternatives IDEXX Laboratories Alternatives DexCom Alternatives STERIS Alternatives Baxter International Alternatives Hologic Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:PODD) was last updated on 11/14/2024 by MarketBeat.com Staff From Our PartnersBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | Sponsored[Urgent] Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it a...Paradigm Press | SponsoredBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredTrump won. Buy this coin now.Juan Villaverde called the top and bottom of every crypto bull market since 2012. He believes Bitcoin will ...Weiss Ratings | SponsoredTrump’s Back, but DC’s Coming for Your Money!Trump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | Sponsored[625,000% Gain] – Are You Ready for the Next Altcoin Boom?All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you k...Crypto Swap Profits | SponsoredWatch this before it gets removed If you missed it, my emergency election broadcast is now available - but will be removed soonPorter & Company | SponsoredNew post-election stock warning from Wall StreetIf you’re holding U.S. stocks, it may be time to brace for impact. The S&P 500 crossed 6,000 for the first ...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Insulet Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Insulet With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free PODD Stock Alerts